Cooley advised EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, on its definitive agreement to be acquired by AstraZeneca (London Stock Exchange/Nasdaq Stockholm/Nasdaq: AZN) for up to $1 billion on a cash- and debt-free basis. The transaction includes an initial payment of $425 million at closing and up to $575 million in contingent consideration based on development and regulatory milestones. The deal is expected to close in the second quarter of 2025, subject to customary closing conditions and regulatory clearances.
EsoBiotec Announces up to $1 Billion Acquisition by AstraZeneca